Glecaprevir Pibrentasvir (Mavyret) prior authorization at Cigna
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Cigna requires prior-authorization documentation for Glecaprevir Pibrentasvir (Mavyret): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Cigna reviews Glecaprevir Pibrentasvir (Mavyret) prior authorizations against its medical policy . Cigna-specific context: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Cigna's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Mental health parity violations
- Step therapy
- Specialty drug prior auth
- OON balance billing disputes
Glecaprevir Pibrentasvir (Mavyret)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Liver fibrosis threshold requirement (now legally indefensible per AASLD-IDSA HCV Guidance)
- Substance-use restrictions / sobriety requirements (HHS and AASLD oppose)
- Specialty pharmacy network restriction
- Prior treatment failure documentation
Brand: Mavyret. Pangenotypic DAA combination (NS3/4A + NS5A inhibitor) for HCV. 8-week regimen for treatment-naive without cirrhosis or with compensated cirrhosis — shortened from 12-week per 2019 FDA label update. Pediatric approval down to age 3.
Manufacturer patient-assistance program: AbbVie Patient Assistance Foundation (Mavyret) — relevant when a Cigna denial sticks and the patient needs bridge access while appealing.
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://cignaforhcp.cigna.com) with the same packet plus an applicable, current clinical source supporting Glecaprevir Pibrentasvir (Mavyret)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Cigna denial on DenialHelp.
Contact Cigna
- Provider portal: https://cignaforhcp.cigna.com
Frequently asked questions
What documentation does Cigna need for Glecaprevir Pibrentasvir (Mavyret) prior auth?
Cigna's typical PA packet for Glecaprevir Pibrentasvir (Mavyret): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Cigna?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for Glecaprevir Pibrentasvir (Mavyret) at Cigna?
Preparation scenarios to check against the current notice and policy include: Mental health parity violations; Step therapy; Specialty drug prior auth. These are not measured frequency claims. For Glecaprevir Pibrentasvir (Mavyret), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
How do I prep for a peer-to-peer with Cigna on Glecaprevir Pibrentasvir (Mavyret)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Glecaprevir Pibrentasvir (Mavyret) PA packet
Open ApprovalHelp — generate a Glecaprevir Pibrentasvir (Mavyret) prior-auth packet tailored to Cigna's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com